TT
BMY icon

Tiedemann Trust’s Bristol-Myers Squibb BMY Stock Holding History

Tiedemann Trust’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-15,000
Closed -$670K – 76
2013
Q2 		$670K Buy
+15,000
New +$651K 0.11% 53

Other funds holding BMY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $677M AUM 27.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tiedemann Trust's BMY Position: Q3 2013 in Review

Tiedemann Trust sold out of Bristol-Myers Squibb (BMY) in Q3 2013, closing a stake of 15,000 shares — an estimated $670K sold.

Tiedemann Trust first reported a position in BMY in Q2 2013 and held it in 1 quarter. The position peaked at $670K in Q2 2013. 1,187 funds tracked by Wall St. Rank hold BMY as of Q3 2013.

  • Tiedemann Trust reported no remaining Bristol-Myers Squibb position as of Q3 2013 after selling out during the quarter.
  • Tiedemann Trust sold 15,000 Bristol-Myers Squibb shares in Q3 2013, an estimated $670K.
  • Tiedemann Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 1 quarter.
  • Tiedemann Trust's Bristol-Myers Squibb position peaked at $670K in Q2 2013.
  • 1,187 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2013.

Based on Tiedemann Trust's 13F filing for Q3 2013, filed 12 Nov 2013.